Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease

• DOI: 10.3389/fimmu.2023.1192827
• Publication Date: 2023-06-24T17:28:51Z
• Authors: So Yoon Choi; Yiyoung Kwon; Sujin Choi; So Mi Lee; Byung-Ho Choe; Ben Kang
• Keywords: Trough (economics)

It is well known that infliximab (IFX) trough levels (TLs) are associated with endoscopic healing (EH) in Crohn's disease (CD). We investigated whether IFX TLs transmural (TH) pediatric patients CD following 1-year treatment. Pediatric treated were included this single-center prospective study. TL tests, magnetic resonance enterography (MRE), and colonoscopies simultaneously conducted after TH was defined as a wall thickness of ≤3 mm without inflammatory signs evaluated using MRE. EH Simple Endoscopic Score for <3 points on colonoscopy. Fifty-six included. observed 60.7% (34/56) 23.2% (13/56) patients, respectively. higher (median, 5.6 vs. 3.4 µg/mL, P = 0.002), whereas showed no significant difference 5.4 4.7 0.574). No between whose intervals shortened or not. Multivariate logistic regression analysis duration to initiation (odds ratio [OR] 1.82, 0.001, OR 0.43, 0.02, respectively). In CD, but not TH. Further studies investigating long-term proactive dosing based therapeutic drug monitoring may clarify an association exists.